Press Releases

DUBLIN--(BUSINESS WIRE)-- The "US Smoking Cessation Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. US Smoking Cessation Market and Competitive Landscape - 2018, provides comprehensive insights into Smoking Cessation pipeline, epidemiology, market

LOS ANGELES--(BUSINESS WIRE)-- The Motor Press Guild (MPG) Board of Directors recently announced a call for nominations for its prestigious 2018 Motor Press Guild “Best of the Year” journalism awards. Now in its 24th year, the awards aim to recognize individuals who have demonstrated automotive journalism excellence during the calendar year. “This is part of a very proud

WASHINGTON--(BUSINESS WIRE)-- The Asbestos Disease Awareness Organization (ADAO) and

DUBLIN--(BUSINESS WIRE)-- The "US Alzheimer's Disease Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. US Alzheimer's Disease Market and Competitive Landscape - 2018, provides comprehensive insights into Alzheimer's Disease pipeline, ep

DUBLIN--(BUSINESS WIRE)-- The "US Psoriasis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. US Psoriasis Market and Competitive Landscape - 2018, provides comprehensive insights into Psoriasis pipeline, epidemiology, market valuations,

DUBLIN--(BUSINESS WIRE)-- The "US Fibromyalgia Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. US Fibromyalgia Market and Competitive Landscape - 2018, provides comprehensive insights into Fibromyalgia pipeline, epidemiology, market va

ELYRIA, Ohio--(BUSINESS WIRE)-- Matthew E. Monaghan, chairman, president and chief executive officer of Invacare Corporation (NYSE:IVC), will present at the 2018 Stephens NY Investment Conference at the Lotte New York Palace Hotel in New York on Thursday, November 8, 2018. The live webcast of the presentation will be available at

DUBLIN--(BUSINESS WIRE)-- The "US Osteoporosis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. US Osteoporosis Market and Competitive Landscape - 2018, provides comprehensive insights into Osteoporosis pipeline, epidemiology, market

DUBLIN--(BUSINESS WIRE)-- The "Mineral Wool Metal-Faced Panel Manufacturers - Global Data Base and Export Listings - 2018" report has been added to ResearchAndMarkets.com's offering. Insulated panel production has seen significant growth in the last 30-plus years. Output, sales, applica

DUBLIN--(BUSINESS WIRE)-- The "Regulatory and procedural aspects of variation submission in Pharmacovigilance" webinar has been added to ResearchAndMarkets.com's offering A variation is a change to the terms of a marketing authorization. All the Pharmaceutical producers and importers in

HEIDELBERG, Germany--(BUSINESS WIRE)-- Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based

DUBLIN--(BUSINESS WIRE)-- The "Global Butanediol Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The global butanediol market to grow at a CAGR of 3.53% during the period 2018-2022. Global Butanediol Market 2018-2022, has been prepared based o

DUBLIN--(BUSINESS WIRE)-- The "Outdoor Free Space Optics In Non-Military/Aerospace Applications - Global Market Forecast" report has been added to ResearchAndMarkets.com's offering. Free Space Optics (FSO) is a line-of-sight (LOS) technology that uses directed LEDs or Laser emitters, wh

BROOKWOOD, Ala.--(BUSINESS WIRE)-- Warrior Met Coal (NYSE: HCC) today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.05 per share to be paid on November 9, 2018, to stockholders of record as of the close of business on November 2, 2018. Warrior Met Coal is a large-scale, low-cost U.S. based producer and exporter of premium hard coking coal (“HCC&rdquo

PHILADELPHIA--(BUSINESS WIRE)-- Context Therapeutics today announced Phase 1 data for its investigational new drug, Apristor® (Onapristone extended release), an oral progesterone receptor antagonist that is being developed for progesterone receptor-positive (PR+) cancers. Data from the study showed that Apristor, a novel extended release formulation of onapristone, was well tolerated and provided